c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

[1]  C. Pritchard,et al.  KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. , 2017, Blood.

[2]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[3]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[4]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[5]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[6]  B. Spencer‐Dene,et al.  Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance , 2013, Cancer cell.

[7]  T. Jacks,et al.  Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. , 2013, Current opinion in immunology.

[8]  R. Boellaard,et al.  Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib , 2013, PloS one.

[9]  E. Moding,et al.  Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice , 2011, Disease Models & Mechanisms.

[10]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[11]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[12]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[13]  W. Kolch,et al.  Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.

[14]  Julian Downward,et al.  RAS Interaction with PI3K: More Than Just Another Effector Pathway. , 2011, Genes & cancer.

[15]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[16]  M. Baccarini,et al.  Targets of Raf in tumorigenesis. , 2010, Carcinogenesis.

[17]  C. Crews,et al.  Chemical Inducers of Targeted Protein Degradation* , 2010, The Journal of Biological Chemistry.

[18]  M. Baccarini,et al.  Raf-1 addiction in Ras-induced skin carcinogenesis. , 2009, Cancer cell.

[19]  A. Bhandoola,et al.  Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. , 2007, Cell stem cell.

[20]  Alcino J. Silva,et al.  Forebrain‐specific knockout of B‐raf kinase leads to deficits in hippocampal long‐term potentiation, learning, and memory , 2006, Journal of neuroscience research.

[21]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[22]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[23]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[24]  C. Pritchard,et al.  MEK kinase activity is not necessary for Raf‐1 function , 2001, The EMBO journal.

[25]  E. Wagner,et al.  Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene , 2001, The EMBO journal.

[26]  E. Wagner,et al.  Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis , 2001, The Journal of experimental medicine.

[27]  P. Angrand,et al.  Improved properties of FLP recombinase evolved by cycling mutagenesis , 1998, Nature Biotechnology.

[28]  U. Rapp,et al.  Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.

[29]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.